Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.

MLA

Reis, Bernhard, et al. “Acute Myeloid Leukemia Patients’ Clinical Response to Idasanutlin (RG7388) Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts.” Haematologica, vol. 101, no. 5, May 2016, pp. e185–88. EBSCOhost, https://doi.org/10.3324/haematol.2015.139717.

APA

Reis, B., Jukofsky, L., Chen, G., Martinelli, G., Zhong, H., So, W. V., Dickinson, M. J., Drummond, M., Assouline, S., Hashemyan, M., Theron, M., Blotner, S., Lee, J.-H., Kasner, M., Yoon, S.-S., Rueger, R., Seiter, K., Middleton, S. A., Kelly, K. R., … Pierceall, W. E. (2016). Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. Haematologica, 101(5), e185–e188. https://doi.org/10.3324/haematol.2015.139717

Chicago

Reis, Bernhard, Lori Jukofsky, Gong Chen, Giovanni Martinelli, Hua Zhong, W Venus So, Michael J Dickinson, et al. 2016. “Acute Myeloid Leukemia Patients’ Clinical Response to Idasanutlin (RG7388) Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts.” Haematologica 101 (5): e185–88. doi:10.3324/haematol.2015.139717.